코르버스 파마슈티컬스, Inc.
DE ˙ DB ˙ US2210151005
€9.94 ↓ -0.31 (-3.02%)
2026-06-05
주가
SecurityDE:C17 / Corvus Pharmaceuticals, Inc.
InstitutionMillennium Management Llc
ManagerIsrael Englander
Latest Disclosed Ownership866,362 shares
Latest Disclosed Value $ 12,674,876
Millennium Management Llc ownership in C17 / Corvus Pharmaceuticals, Inc.

On May 15, 2026 - Millennium Management Llc filed a 13F-HR form disclosing ownership of 866,362 shares of Corvus Pharmaceuticals, Inc. (DE:C17) valued at $9,824,545 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 688,770 shares of Corvus Pharmaceuticals, Inc.. This represents a change in shares of 25.78% during the quarter. The current value of the position is $8,611,638 USD.

Millennium Management Llc has a history of taking positions in derivatives of the underlying security (C17) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:C17 / Corvus Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CORVUS PHARMACEUTICALS COM 221015100 866,362 177,592 25.78 12,675 139.00 0.0053
2026-02-17 2025-12-31 13F CORVUS PHARMACEUTICALS COM 221015100 688,770 688,770 5,304 0.0022
2025-08-14 2025-06-30 13F CORVUS PHARMACEUTICALS COM 221015100 0 -1,637,138 -100.00 0 -100.00
2025-05-15 2025-03-31 13F CORVUS PHARMACEUTICALS COM 221015100 1,637,138 1,482,237 956.89 5,206 528.74 0.0028
2025-02-14 2024-12-31 13F CORVUS PHARMACEUTICALS COM 221015100 154,901 -156,387 -50.24 829 -49.60 0.0004
2024-11-14 2024-09-30 13F CORVUS PHARMACEUTICALS COM 221015100 311,288 106,690 52.15 1,644 341.67 0.0008
2024-08-14 2024-06-30 13F CORVUS PHARMACEUTICALS COM 221015100 204,598 181,317 778.82 372 807.32 0.0002
2024-05-15 2024-03-31 13F CORVUS PHARMACEUTICALS COM 221015100 23,281 -17,554 -42.99 41 -42.25 0.0000
2024-02-14 2023-12-31 13F CORVUS PHARMACEUTICALS COM 221015100 40,835 -67,189 -62.20 72 -54.78 0.0000
2023-11-14 2023-09-30 13F CORVUS PHARMACEUTICALS COM 221015100 108,024 108,024 158 0.0001
2023-08-14 2023-06-30 13F CORVUS PHARMACEUTICALS COM 221015100 0 -2,029,423 -100.00 0 -100.00
2023-05-15 2023-03-31 13F CORVUS PHARMACEUTICALS COM 221015100 2,029,423 129,907 6.84 1,847 14.37 0.0011
2023-02-14 2022-12-31 13F CORVUS PHARMACEUTICALS COM 221015100 1,899,516 -365,796 -16.15 1,615 -12.89 0.0009
2022-11-14 2022-09-30 13F CORVUS PHARMACEUTICALS COM 221015100 2,265,312 -422,631 -15.72 1,854 -30.33 0.0011
2022-08-15 2022-06-30 13F CORVUS PHARMACEUTICALS COM 221015100 2,687,943 -35,596 -1.31 2,661 -40.43 0.0017
2022-05-16 2022-03-31 13F CORVUS PHARMACEUTICALS COM 221015100 2,723,539 -196,520 -6.73 4,467 -36.52 0.0024
2022-02-14 2021-12-31 13F CORVUS PHARMACEUTICALS COM 221015100 2,920,059 2,331,787 396.38 7,037 147.17 0.0036
2021-11-15 2021-09-30 13F CORVUS PHARMACEUTICALS COM 221015100 588,272 456,837 347.58 2,847 711.11 0.0017
2021-08-16 2021-06-30 13F CORVUS PHARMACEUTICALS COM 221015100 131,435 32,339 32.63 351 15.08 0.0002
2021-05-17 2021-03-31 13F CORVUS PHARMACEUTICALS COM 221015100 99,096 -22,522 -18.52 305 -29.56 0.0002
2021-02-16 2020-12-31 13F CORVUS PHARMACEUTICALS COM 221015100 121,618 -259,525 -68.09 433 -71.66 0.0003
2020-11-16 2020-09-30 13F CORVUS PHARMACEUTICALS COM 221015100 381,143 -811,599 -68.04 1,528 -52.90 0.0019
2020-08-14 2020-06-30 13F CORVUS PHARMACEUTICALS COM 221015100 1,192,742 160,983 15.60 3,244 49.01 0.0044
2020-05-14 2020-03-31 13F CORVUS PHARMACEUTICALS COM 221015100 1,031,759 231,929 29.00 2,177 -49.97 0.0049
2020-02-14 2019-12-31 13F CORVUS PHARMACEUTICALS COM 221015100 799,830 -152,367 -16.00 4,351 51.81 0.0054
2019-11-14 2019-09-30 13F CORVUS PHARMACEUTICALS COM 221015100 952,197 877,462 1,174.10 2,866 923.57 0.0045
2019-08-15 2019-06-30 13F/A-1 CORVUS PHARMACEUTICALS COM 221015100 74,735 55,905 296.89 280 268.42 0.0004
2019-08-14 2019-06-30 13F CORVUS PHARMACEUTICALS COM 221015100 74,735 55,905 280
2019-05-14 2019-03-31 13F CORVUS PHARMACEUTICALS COM 221015100 18,830 -41,418 -68.75 76 -65.61 0.0001
2019-02-15 2018-12-31 13F/A-1 CORVUS PHARMACEUTICALS COM 221015100 60,248 22,878 61.22 221 -31.15 0.0003
2019-02-14 2018-12-31 13F CORVUS PHARMACEUTICALS COM 221015100 60,248 221
2018-11-14 2018-09-30 13F CORVUS PHARMACEUTICALS COM 221015100 37,370 -308,204 -89.19 321 -91.54 0.0004
2018-08-14 2018-06-30 13F CORVUS PHARMACEUTICALS COM 221015100 345,574 -259,729 -42.91 3,794 -45.64 0.0049
2018-05-15 2018-03-31 13F CORVUS PHARMACEUTICALS COM 221015100 605,303 546,286 925.64 6,979 1,042.23 0.0093
2018-02-14 2017-12-31 13F CORVUS PHARMACEUTICALS COM 221015100 59,017 37,998 180.78 611 82.39 0.0008
2017-11-14 2017-09-30 13F CORVUS PHARMACEUTICALS COM 221015100 21,019 21,019 335 0.0005
2017-08-14 2017-06-30 13F CORVUS PHARMACEUTICALS COM 221015100 0 -22,853 -100.00 0 -100.00
2017-05-15 2017-03-31 13F CORVUS PHARMACEUTICALS COM 221015100 22,853 -36,034 -61.19 475 -43.59 0.0009
2017-02-14 2016-12-31 13F CORVUS PHARMACEUTICALS COM 221015100 58,887 -51,167 -46.49 842 -53.48 0.0018
2016-11-14 2016-09-30 13F CORVUS PHARMACEUTICALS COM 221015100 110,054 110,054 0.00 1,810 0.0030
2016-08-15 2016-06-30 13F CORVUS PHARMACEUTICALS COM 221015100 0 -40,701 -100.00 0 -100.00
2016-05-16 2016-03-31 13F CORVUS PHARMACEUTICALS COM 221015100 40,701 40,701 590 0.0015
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2025-08-14 2025-06-30 13F CORVUS PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-05-15 2025-03-31 13F CORVUS PHARMACEUTICALS COM Call 121,200 -33.11 385 -60.27 n/a n/a n/a
2025-02-14 2024-12-31 13F CORVUS PHARMACEUTICALS COM Call 181,200 18.59 969 20.22 n/a n/a n/a
2024-11-14 2024-09-30 13F CORVUS PHARMACEUTICALS COM Call 152,800 807 n/a n/a n/a
2022-02-14 2021-12-31 13F CORVUS PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2021-11-15 2021-09-30 13F CORVUS PHARMACEUTICALS COM Call 103,100 499 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2025-11-14 2025-09-30 13F CORVUS PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2025-08-14 2025-06-30 13F CORVUS PHARMACEUTICALS COM Put 150,000 200.00 600 277.36 n/a n/a n/a
2025-05-15 2025-03-31 13F CORVUS PHARMACEUTICALS COM Put 50,000 159 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.